• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Deep (Brain) Thoughts with Medtronic's Neuromodulation President

    Grab and Go: Examining the Thrombectomy Device Market

    Fine Print: A Discourse on Additive Manufacturing

    MPO's 2022 Medtech Industry Year in Review

    Micro Molding for Medtech Is Miniature Magic
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    Study: Smartphone Therapeutic Helps Improve Fibromyalgia in Patients

    Sightpath Medical Acquires Accusite Surgical

    Sissel Lønning Andresen Named LINK Medical CEO

    CARMAT Resumes Commercial Artificial Heart Implants

    Junkosha Plans New Facility in Kasama, Japan
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Deep (Brain) Thoughts with Medtronic's Neuromodulation President

    Grab and Go: Examining the Thrombectomy Device Market

    Fine Print: A Discourse on Additive Manufacturing

    MPO's 2022 Medtech Industry Year in Review

    Micro Molding for Medtech Is Miniature Magic
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Reflections on 2022 and What’s Ahead for Medtech: MPO Sounding Board

    3 Ways to Prepare for ISO 13485/Part 820 Harmonization

    A New Home for Theranos' Elizabeth Holmes?

    Health Cost Drivers for Large Employers

    Braving Change: Facing Fears in the Midst of Major Transitions
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Forefront Medical Technology

    NDH Medical Inc.

    Fusion Biotec Inc.

    Halkey-Roberts Corporation

    JBC Technologies
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    How Artificial Intelligence Can Combat Key Issues Impacting Healthcare

    Why Advanced Sensors Are Crucial Within Medical Pumps

    How Artificial Intelligence Could Help Prevent 80% of Chronic Diseases

    4 Ways to Use Injection Molding in Medical Device Manufacturing

    Telemedicine and Connectivity to Drive Material Innovation in the Near Future
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Forefront Medical Technology

    NDH Medical Inc.

    Fusion Biotec Inc.

    Halkey-Roberts Corporation

    JBC Technologies
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    Profound Medical Corp. Completes Patient Enrollment in TACT Pivotal Clinical Trial

    Trial has enrolled 110 prostate cancer patients across 13 research sites in the United States, Canada, and Europe.

    Related Content
    • HIMSS 2021: Siemens Healthineers Adds Cell Lung Cancer Pathway for AI-Pathway Companion
    • Promaxo Taps Srirama Venkataraman as VP of Clinical Research & Strategy
    • Ibex Medical Analytics Earns CE Mark for Galen Breast Solution
    • Philips, Ibex Medical Analytics Partner to Accelerate Adoption of AI-Powered Digital Pathology
    • Urinary Tract Stent Market to Lose 11.4 Percent in Revenue Due to Coronavirus
    Globe Newswire02.26.18
    Profound Medical Corp., developer of a therapeutic platform that provides the precision of real-time MR imaging combined with the safety and accuracy of directional (inside-out) and focused (outside-in) ultrasound technology for incision-free ablation of diseased tissue, has completed patient enrollment in the TACT (TULSA-PRO Ablation Clinical Trial) pivotal study designed to further evaluate the safety and efficacy of TULSA-PRO to ablate prostate tissue in patients with localized, organ-confined prostate cancer.
     
    TACT, a prospective, open-label, single-arm pivotal clinical study, has enrolled 110 prostate cancer patients across 13 research sites in the United States, Canada and Europe. If successful, TACT is expected to support Profound’s application to the U.S. Food and Drug Administration (FDA) for clearance to market this technology in the United States.
     
    The primary efficacy endpoint of TACT is the proportion of patients achieving a post-treatment prostate-specific antigen (“PSA”) reduction greater or equal to 75 percent of their pre-treatment baseline value. The company’s pre-established performance goal for the success proportion is 50 percent of patients. Based on a preliminary analysis performed by the company, of the first 63 evaluable patients, the median PSA reduction to-date is 93 percent, and 92 percent (58 out of 63) have achieved the PSA reduction success proportion. 
     
    The primary safety endpoint is the frequency and severity of adverse events, with additional secondary endpoints focused on quality-of-life side effects commonly associated with current prostate cancer therapies, such as erectile dysfunction and urinary incontinence. As the standard evaluation period for these side effects is 12 months post-treatment, the sample size of evaluable patients is not yet large enough to assess.
     
    “It is very exciting the TACT trial has completed accrual in such a timely manner,” said Dr. Scott Eggener, TACT’s principal investigator; professor of Surgery and Radiology, and director of the Prostate Cancer Program at the University of Chicago (Ill.). “Today, the gap between active surveillance and radical treatments such as surgery and radiation is often too wide for both clinicians and patients. TULSA-PRO is a minimally-invasive and image-guided option intending to ablate low and intermediate risk prostate cancers with the goal of reducing the risk of side-effects commonly associated with other treatments. There has been a smooth collaboration between the various clinical sites and Profound and we all are looking forward to seeing the final results.”
     
    “We are pleased patient enrollment has now been completed and look forward to sharing the full clinical results of this pivotal study with our stakeholders in due time,” commented Arun Menawat, Profound’s CEO. “We expect data from TACT will help pave the path for the successful commercialization of TULSA-PRO in the United States and further drive clinical adoption of the technology in Europe.”
     
    Profound Medical is committed to creating the combination of real-time magnetic resoning guidance as the imaging platform and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patients and clinicians in many anatomies and disease states, including prostate cancer, uterine fibroids, and bone metastases. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives.
     
    Profound Medical is commercializing a technology, TULSA-PRO, which combines real-time magnetic resonance (MR) imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO is CE marked and Profound Medical is currently conducting a pilot commercial launch of the technology in key European and other CE mark jurisdictions. The company is also sponsoring a multicenter, prospective FDA-registered clinical trial, TACT, which, if successful, is expected to support its application to the FDA for clearance to market TULSA-PRO in the United States.
     
    Profound Medical is also commercializing Sonalleve, an innovative therapeutic platform that combines real-time MR imaging and thermometry with thermal ultrasound to enable precise and incision-free ablation of diseased tissue. Sonalleve is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. The company is also in the early stages of exploring additional potential treatment markets for Sonalleve, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy, where the technology has been shown to have clinical application.
    Related Searches
    • medical
    • technology
    • prostate cancer
    • surgery
    Suggested For You
    HIMSS 2021: Siemens Healthineers Adds Cell Lung Cancer Pathway for AI-Pathway Companion HIMSS 2021: Siemens Healthineers Adds Cell Lung Cancer Pathway for AI-Pathway Companion
    Promaxo Taps Srirama Venkataraman as VP of Clinical Research & Strategy Promaxo Taps Srirama Venkataraman as VP of Clinical Research & Strategy
    Ibex Medical Analytics Earns CE Mark for Galen Breast Solution Ibex Medical Analytics Earns CE Mark for Galen Breast Solution
    Philips, Ibex Medical Analytics Partner to Accelerate Adoption of AI-Powered Digital Pathology Philips, Ibex Medical Analytics Partner to Accelerate Adoption of AI-Powered Digital Pathology
    Urinary Tract Stent Market to Lose 11.4 Percent in Revenue Due to Coronavirus Urinary Tract Stent Market to Lose 11.4 Percent in Revenue Due to Coronavirus
    Using Revenue-Based Financing to Grow in the Pandemic Using Revenue-Based Financing to Grow in the Pandemic
    Quality Nightmares #35: The Rejection Quality Nightmares #35: The Rejection
     Cardiovascular Systems Expands Product Portfolio to Support Peripheral, Coronary Interventions Cardiovascular Systems Expands Product Portfolio to Support Peripheral, Coronary Interventions
    Quality Nightmares #34: The FDA Auditor Quality Nightmares #34: The FDA Auditor
    Feeding the Medtech Innovation Pipeline Feeding the Medtech Innovation Pipeline
    The The 'New' Alternative 510k—Mike on Medtech
     First Patients Implanted With Axonics Sacral Neuromodulation System in FDA Pivotal Study First Patients Implanted With Axonics Sacral Neuromodulation System in FDA Pivotal Study
    FDA Warns BD About Blood Collection Tubes Used in Lead Testing Kit FDA Warns BD About Blood Collection Tubes Used in Lead Testing Kit
    Baxter Makes $153M Acquisition to Broaden Surgical Products Portfolio Baxter Makes $153M Acquisition to Broaden Surgical Products Portfolio
    FDA Issues Class I Recall for Sterilmed Reprocessed Agilis Steerable Introducer Sheath FDA Issues Class I Recall for Sterilmed Reprocessed Agilis Steerable Introducer Sheath

    Related Breaking News

    • Chronic Disease
      HIMSS 2021: Siemens Healthineers Adds Cell Lung Cancer Pathway for AI-Pathway Companion

      HIMSS 2021: Siemens Healthineers Adds Cell Lung Cancer Pathway for AI-Pathway Companion

      Assists multidisciplinary teams by facilitating patient management and case reviews in a single dashboard.
      Siemens Healthineers 08.10.21

    • Promaxo Taps Srirama Venkataraman as VP of Clinical Research & Strategy

      Promaxo Taps Srirama Venkataraman as VP of Clinical Research & Strategy

      With previous roles at Philips and Stryker, Dr. Venkataraman will bring his expertise to Promaxo’s MRI and robotic platform.
      Business Wire 07.30.21

    • Chronic Disease
      Ibex Medical Analytics Earns CE Mark for Galen Breast Solution

      Ibex Medical Analytics Earns CE Mark for Galen Breast Solution

      Demonstrates very high accuracy in detecting multiple types of breast cancer in a blinded study.
      Charles Sternberg, Assistant Editor 06.01.21


    • Digital Health
      Philips, Ibex Medical Analytics Partner to Accelerate Adoption of AI-Powered Digital Pathology

      Philips, Ibex Medical Analytics Partner to Accelerate Adoption of AI-Powered Digital Pathology

      Combination of Philips’ digital pathology solutions and Ibex’s AI-powered Galen platform has improved reporting efficiency by 27 percent.
      Michael Barbella, Managing Editor 05.27.21

    • Urinary Tract Stent Market to Lose 11.4 Percent in Revenue Due to Coronavirus

      Urinary Tract Stent Market to Lose 11.4 Percent in Revenue Due to Coronavirus

      Boston Scientific Corp., Cook Group and BD will be most impacted by the deficit.
      GlobalData 11.12.20

    Loading, Please Wait..

    Trending
    • The Future Of Biomedical Engineering Advancements
    • Medtronic's Recall Of Mahurkar Catheters Is Class I
    • Cirtec Medical Corporation Acquires Precision Components Business From QMD
    • Environmental Sustainability Becoming Increasingly Important To Medtech Industry
    • 5 Ways Plastics Revolutionized The Healthcare Industry
    Breaking News
    • Study: Smartphone Therapeutic Helps Improve Fibromyalgia in Patients
    • Sightpath Medical Acquires Accusite Surgical
    • Sissel Lønning Andresen Named LINK Medical CEO
    • CARMAT Resumes Commercial Artificial Heart Implants
    • Junkosha Plans New Facility in Kasama, Japan
    View Breaking News >
    CURRENT ISSUE

    November 2022

    • MPO's 2022 Year in Review
    • Fine Print: A Discourse on Additive Manufacturing
    • Grab and Go: Examining the Thrombectomy Device Market
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    GOED Elects New Board Officers for 2023
    Aspire Hires Darrec Jones as VP of Business Development
    Pycnogenol Supplementation Linked to Better Hair Density in Menopausal Women
    Coatings World

    Latest Breaking News From Coatings World

    ROSS Offers Heavy-Duty Three Roll Mills for High Viscosity Dispersions
    PPG Achieves ISO 14001 Certification of Environmental Management System
    AmCoat’s Rhino Shield and Floor Shield Break Records in 2022
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Sissel Lønning Andresen Named LINK Medical CEO
    CARMAT Resumes Commercial Artificial Heart Implants
    Junkosha Plans New Facility in Kasama, Japan
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Merck Revenues Up 22% for the Year to $59.3B
    BioNTech SE Completes Proprietary Plasmid DNA Manufacturing Facility in Marburg, Germany
    Dragonfly Therapeutics Appoints Joseph Eid as President of Research & Development
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    e.l.f. Beauty Net Sales Grow 49% in Third Quarter of 2023
    DOVE Introduces ‘Next-Gen’ Body Wash in Sleek New Sustainable Bottle
    Ariana Grande Agrees to Purchase Assets Tied to r.e.m. beauty from Forma Brands
    Happi

    Latest Breaking News From Happi

    CVS Introduces New Beauty, Personal Care Brand One+Other
    Sharon Personal Care Expands Green Product Portfolio and Formulation Capabilities
    Ecolab Enters Consumer Retail with New Ecolab Scientific Clean Brand at Home Depot
    Ink World

    Latest Breaking News From Ink World

    International Paper Named to Fortune's List of World's Most Admired Companies
    Flint Group Launches Sustainable UV LED Dual Cure Ink
    Smurfit Kappa's Sustainable Solutions Take Home Eight WorldStar Awards
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    PPC Flexible Packaging acquires Israel-based StePac, MAPfresh Holdings
    Flint Group launches sustainable UV LED dual cure ink
    KB Folie invests in first ThermoFlexX imager
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Qvin Menstrual Blood Diagnostic Device Receives FDA Approval in Thailand
    Andritz, KCF Technologies Form Agreement
    Freudenberg e-Power Systems, LG Energy Solution Announce Partnership
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Adrian Tyndall Joins Axogen's Board of Directors
    ADSM-Synchro Medical Acquired by Tyber Medical
    Solid Growth Ahead for Orthopedic Power Tools Market
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Infineon Concludes Very Profitable 1Q 2023
    LOPEC 2023: Here are the Highlights for Printed Electronics
    Employee-Led Giving at ORNL Provides $937,000 to Area Nonprofits in 2022

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login